封面
市場調查報告書
商品編碼
1684650

CAR-T 細胞療法市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

CAR T-cell Therapy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: | 出版商: Global Market Insights Inc. | 英文 138 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球 CAR-T 細胞療法市場價值為 43 億美元,預計將經歷強勁的成長軌跡,2025 年至 2034 年的複合年成長率將達到 30.5%。嵌合抗原受體 (CAR) T 細胞療法正在徹底改變癌症治療,標誌著腫瘤學的一個重要里程碑。這種先進的免疫療法涉及對患者 T 細胞進行基因改造,以便更好地瞄準和消滅癌細胞。 CAR T 細胞療法不僅為患者帶來了新的希望,也改變了我們治療某些癌症的方式。隨著技術的日益普及和進步,這個市場有望不斷擴張。

CAR-T 細胞療法市場 - IMG1

全球市場分為幾種主要產品,包括 Abecma、Breyanzi、Carvykti、Kymriah、Tecartus、Yescarta 等。其中,Yescarta脫穎而出,成為市場領導者,2024年佔了32.5%的市佔率。 Yescarta佔據市場主導地位的主要原因在於它對B細胞淋巴瘤患者已被證明有效,特別是在傳統治療方法往往無效的複發或難治性病例中。隨著越來越多的患者尋求治療惡性癌症的替代療法,對 Yescarta 的需求持續成長,進一步鞏固了其在該領域的領先地位。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 43億美元
預測值 611億美元
複合年成長率 30.5%

從適應症來看,CAR-T 細胞治療市場分為白血病、淋巴瘤、多發性骨髓瘤等,其中淋巴瘤的收入最高,2024 年將達到 24 億美元。瀰漫性大 B 細胞淋巴瘤 (DLBCL) 是一種常見的非何杰金氏淋巴瘤,是這一成長的主要貢獻者。 DLBCL 在接受傳統療法治療後復發率較高,這推動了對 CAR T 細胞療法的需求,這種療法在針對和治療侵襲性淋巴瘤方面表現出了顯著的療效。因此,CAR-T 細胞療法越來越被視為治療這些棘手癌症類型的重要解決方案,為別無選擇的患者帶來了新的希望。

預計到 2034 年,美國 CAR-T 細胞療法市場規模將達到 250 億美元,在支持性監管框架的推動下,市場將實現強勁成長。美國食品藥物管理局(FDA)在 CAR-T 細胞療法的快速開發和商業化中發揮了關鍵作用,透過突破性療法認定、孤兒藥地位和快速通道等加速核准流程提供關鍵的監管支持。這些措施加速了CAR-T細胞療法的普及,確保需要救命治療的患者能夠及時獲得治療。

目錄

第 1 章:方法論與範圍

第 2 章:執行摘要

第 3 章:產業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 人口中癌症惡性腫瘤病例不斷增加
      • 針對性治療傾向日益增強
      • 擁有強大的產品線,已獲得跨地區監管部門的批准
    • 產業陷阱與挑戰
      • 藥品成本高阻礙市場成長
      • CAR-T 細胞療法的副作用
  • 成長潛力分析
  • 監管格局
  • 技術格局
  • 未來市場趨勢
  • 差距分析
  • 波特的分析
  • PESTEL 分析

第4章:競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 策略儀表板

第 5 章:市場估計與預測:按產品,2021 年至 2034 年

  • 主要趨勢
  • Abecma(idecabtagene vicleucel)
  • Breyanzi(lisocabtagene maraleucel)
  • Carvykti(ciltacabtagene autoleucel)
  • Kymriah(tisagenlecleucel)
  • Tecartus(brexucabtagene autoleucel)
  • Yescarta(axicabtagene ciloleucel)
  • 其他產品

第 6 章:市場估計與預測:按適應症,2021 年至 2034 年

  • 主要趨勢
  • 白血病
  • 淋巴瘤
  • 多發骨髓瘤
  • 其他適應症

第 7 章:市場估計與預測:按人口統計,2021 年至 2034 年

  • 主要趨勢
  • 成年人
  • 兒科

第 8 章:市場估計與預測:依最終用途,2021 年至 2034 年

  • 主要趨勢
  • 醫院
  • 癌症治療中心
  • 專科診所

第 9 章:市場估計與預測:按地區,2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章:公司簡介

  • Allogene Therapeutics
  • Autolus Therapeutics
  • bluebird bio
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics
  • Gilead Sciences
  • GSK plc.
  • ImmunoAct
  • Johnson & Johnson
  • JW Therapeutics (Shanghai)
  • Medigene AG
  • Merck KGaA
  • Novartis AG
  • Sangamo Therapeutics
  • Sorrento Therapeutics
簡介目錄
Product Code: 13065

The Global CAR T-Cell Therapy Market, valued at USD 4.3 billion in 2024, is projected to experience a robust growth trajectory, with an impressive CAGR of 30.5% from 2025 to 2034. Chimeric Antigen Receptor (CAR) T-cell therapy is revolutionizing cancer treatment, marking a significant milestone in oncology. This advanced form of immunotherapy involves the genetic modification of a patient's T-cells to better target and eliminate cancer cells. CAR T-cell therapy is not only offering new hope for patients but also changing the way we approach the treatment of certain cancers. With its growing adoption and advancements in technology, this market is poised for continuous expansion.

CAR T-cell Therapy Market - IMG1

The global market is divided into several key products, including Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta, and others. Among these, Yescarta stands out as the market leader, capturing 32.5% of the total market share in 2024. The primary reason for Yescarta's market dominance lies in its proven effectiveness for patients with B-cell lymphomas, particularly in relapsed or refractory cases where traditional treatments often fall short. As more patients seek alternatives for aggressive forms of cancer, the demand for Yescarta continues to grow, further cementing its leadership in the space.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$4.3 Billion
Forecast Value$61.1 Billion
CAGR30.5%

In terms of indications, the CAR T-cell therapy market is categorized into leukemia, lymphoma, multiple myeloma, and others, with lymphoma generating the highest revenue of USD 2.4 billion in 2024. Diffuse large B-cell lymphoma (DLBCL), a common form of non-Hodgkin lymphoma is a major contributor to this growth. DLBCL's high relapse rates following conventional therapies have driven demand for CAR T-cell treatments, which have shown remarkable efficacy in targeting and treating aggressive lymphoma. As a result, CAR T-cell therapies are increasingly viewed as a vital solution in managing these challenging cancer types, offering new hope to patients with few options left.

The U.S. CAR T-cell therapy market is expected to reach USD 25 billion by 2034, with strong growth fueled by supportive regulatory frameworks. The U.S. Food and Drug Administration (FDA) has played a key role in the rapid development and commercialization of CAR T-cell therapies, providing critical regulatory support through expedited approval processes such as Breakthrough Therapy Designations, Orphan Drug status, and Fast Track pathways. These initiatives have fast-tracked the availability of CAR T-cell therapies, ensuring timely access for patients in need of life-saving treatments.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing cases of cancer malignancies across population
      • 3.2.1.2 Rising inclination towards targeted treatment
      • 3.2.1.3 Robust product pipeline with regulatory approvals across geographies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High drug cost impedes the market growth
      • 3.2.2.2 Side-effects of CAR T-cell therapy
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Abecma (idecabtagene vicleucel)
  • 5.3 Breyanzi (lisocabtagene maraleucel)
  • 5.4 Carvykti (ciltacabtagene autoleucel)
  • 5.5 Kymriah (tisagenlecleucel)
  • 5.6 Tecartus (brexucabtagene autoleucel)
  • 5.7 Yescarta (axicabtagene ciloleucel)
  • 5.8 Other products

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Leukemia
  • 6.3 Lymphoma
  • 6.4 Multiple myeloma
  • 6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Demographic, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Adults
  • 7.3 Pediatric

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Cancer treatment centers
  • 8.4 Specialty clinics

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Allogene Therapeutics
  • 10.2 Autolus Therapeutics
  • 10.3 bluebird bio
  • 10.4 Bristol-Myers Squibb Company
  • 10.5 CRISPR Therapeutics
  • 10.6 Gilead Sciences
  • 10.7 GSK plc.
  • 10.8 ImmunoAct
  • 10.9 Johnson & Johnson
  • 10.10 JW Therapeutics (Shanghai)
  • 10.11 Medigene AG
  • 10.12 Merck KGaA
  • 10.13 Novartis AG
  • 10.14 Sangamo Therapeutics
  • 10.15 Sorrento Therapeutics